88N-0258 PRESCRIPTION DRUG MARKETING ACT OF 1987 GUIDELINE
REF 1 OMB Review on 12/3/99 Vol#: 7
89P-0399 ANDA Suitability re: Carbamazepine Suspension 200 mg/5 ml
92N-0297 Prescription Drug Marketing Act of 1987, Drug Amds of 1992
REF 1 OMB Review on 12/3/99 Vol#: 9
95N-0308 Inapplicability of the Dietary Supplement Health & Ed. Act t
C 425 Media Services, Inc. Vol#: 13
C 426 Jim & Joyce Berry Vol#: 13
C 427 Mrs. Carol J. Rpoer Vol#: 13
C 428 Patricia A. Proudman Vol#: 13
C 429 Dianne Hicks et al Vol#: 13
C 430 Christine L. O'Rourke Vol#: 13
C 431 Sherrie L. Nielsen Vol#: 13
C 432 Cynthia Cobb Vol#: 13
C 433 Caryn J. Hayden Vol#: 13
C 434 Lee E. Heller, Ph.D. Vol#: 13
C 435 Mr. & Mrs. Roger Adams Vol#: 13
C 436 Marilyn E. Harmer Vol#: 13
95S-0316 75-Day Premarket Notifications for New Dietary Ingredients
RPT 106 Power Africa, Inc. Vol#: 80
RPT 107 Power Africa, Inc. Vol#: 80
RPT 108 Power Africa, Inc. Vol#: 80
RPT 109 Power Africa, Inc. Vol#: 80
RPT 110 OmegaTech, Inc. Vol#: 81
RPT 111 Soft Gel Technologies, Inc. Vol#: 80
RPT 112 PharmaSe, Inc. Vol#: 80
97N-0023 Chlorofluorocarbon Propellants in Self-Pressurized Container
REF 2 OMB Review on 7/24/02 Vol#: 201
98D-1146 Microbial effects of antimicrobial new animal drugs/human sa
EAPE59 FDA CVM HFV-157 Vol#: 4
EAPE60 Animal Health Institute Vol#: 4
EAPE61 FDA/Center for Veterinary Medicine Vol#: 4
EAPE64 Abbott Laboratories Vol#: 4
EAPE66 Alliance for the Prudent Use of Antibiot Vol#: 4
EAPE68 Animal Health Institute Vol#: 4
98N-0750 Electronic Reporting of Postmarket Adverse Drug Reactions
REF 1 OMB Review on 11/5/98 Vol#: 1
99P-5106 Identify Sources of Natural Flavorings
C 18 Trent Bower Vol#: 2
00N-1463 Labeling Requirements for Systemic Antibacterial Drug Produc
REF 1 OMB Review on 9/19/00 Vol#: 1
01P-0120 Ban Unsafe IV Catheters and other Devices
C 28 Lorraine M. Harkavy Vol#: 1
01P-0396 Request that FDA ban the production and sale of all ephedra
C 5 Thomas N. Tiedt, Ph.D. Vol#: 1
02N-0209 Governing First Amendment Case Law
02P-0139 Arava (leflunomide;Aventis) remove from the market
LET 1 HFD-1 to Public Citizen Vol#: 1
02P-0141 ANDA for 1.2 mg estropipate (1.2 mg sodium estrone sulfate)
PAV 1 HFD-600 to Women First Healthcare Vol#: 1
02P-0148 ANDA for Fenofibrate Tablets (Tricor)
PAV 1 HFD-600 to Lavender Consulting Services Vol#: 1
02P-0270 Suitability Petition for Hydrocodone Bitartrate/Ibuprofen 5
PAV 1 HFD-600 to SciRegs Consulting Vol#: 1
02P-0424 ANDA for Loperamide Hydrochloride 1 mg Soft Gelatin Capsules
CP 1 Banner Pharmacaps Inc. Vol#: 1
02V-0425 Laser Light Show
ACK 1 HFA-305 Vol#: 1
VAR 1 MGM Grand Hotel Vol#: 1